Going Global | Chinese Companies Abroad | NewTimeSpace

On 12 Nov 2026, JD-SW (09618.HK) completed its CECONOMY takeover at EUR4.60 per share, paying EUR1.335bn for 59.8% and consolidating it from that date.
On 11 November 2026, Ascletis-B (01672.HK) said it filed an IND with the US FDA for ASC30_39 FDC in obesity, a once-daily oral fixed-dose combination of the GLP-1R agonist ASC30 and the selective amylin receptor agonist ASC39, the first oral GLP-1 and amylin combination to file an IND.
On 11 November 2026, Abbisko-B (02256.HK) said its CSF-1R inhibitor Pimjetmi (PIMJETMI) won FDA approval for symptomatic TGCT in adults, its fourth marketing approval after China, Canada and Switzerland. The Phase III study showed a 56% objective response rate at week 25, and the first US sale triggers a US$20 million milestone.
On 10 November 2026, SIS INT'L (00529.HK) said its main Thai unit will take 80% of SiS Technologies Vietnam by subscribing to new shares for USD 800,000.
On 9 November 2026, GRAPHEX GROUP (06128.HK) agreed to sell Graphex Technologies LLC to M2i Global for USD 100 million in cash and shares, payable in stages.
On 6 November 2026, CHALCO said its board approved an RMB6.55557 billion EPC contract with CHALIECO for the Guinea alumina project, a connected transaction.
GUOCO GROUP (00053.HK) said unit GLS signed a JV agreement with Intrepid and BDPL to develop a Singapore site on a 40:60 basis, contributing HKD 509 million.
FOSUN PHARMA (02196.HK) said unit Henlius won ethics approval and TGA filing for a Phase I trial of HLX109 in generalized pustular psoriasis, a first worldwide.
On 4 November 2026, SBP GROUP (01177.HK) licensed six preclinical assets to Boehringer Ingelheim for US$358 million upfront and up to US$7 billion milestones.
On 4 November 2026, CSTONE PHARMA-B (02616.HK) will lead China and Australia Phase I trials of a first-in-class DDR asset under a Kimia pact.
On 4 November 2026, GENFLEET-B (02595.HK) said GFH276 combination therapies won CDE trial approval or completed TGA filing in Australia for RAS-mutant cancers.
On 3 November 2026, CMS (00867.HK) said Singapore's HSA approved Lumirix, its ruxolitinib cream, for non-segmental vitiligo, the first topical drug there.
On 3 November 2026, DIRECT DRIVE (06731.HK) signed a three-year pact with KOSDAQ-listed Everybot covering marketing, joint R&D and Korea distribution.
ALPHAMAB-B (09966.HK) said the FDA cleared JSKN021, its EGFR/HER3 bispecific antibody dual-payload ADC, for a Phase I clinical study.
HUTCHMED (00013.HK) said its savolitinib plus osimertinib combination for MET-driven EGFR-mutant lung cancer was accepted in Europe and Japan, backed by the SAFFRON trial.
On 30 October 2026, BOAN BIOTECH (06955.HK) struck a licensing deal for its denosumab 60mg (BA6101) in Japan, gaining upfront, milestone and royalty payments.
Printed By: NewTimeSpace Media Limited
Address: 19H Maxgrand Plaza, No.3 Tai Yau Street, San Po Kong, Kowloon,HK
Email: contact@newtimespace.com